Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut hormone may control Post-Meal blood pressure drops

NCT ID NCT06934473

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how a natural gut hormone called GIP affects blood pressure after a meal. Sixteen healthy adults will receive either a GIP-blocking drug, a GIP-activating drug, or a placebo during a tilt-table test. The goal is to see if blocking or boosting GIP changes how blood pressure responds after eating.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GIP(3-30)NH2 (a blocker of the GIP hormone receptor) and GIP(1-42) (an activator of the GIP hormone receptor)
What this could lead to
If successful, this could clarify how the gut hormone GIP influences blood pressure after meals, potentially pointing toward new ways to manage dizziness or fainting.
What could go wrong
This is a very small, early-stage study in healthy volunteers, not patients. It is designed to understand basic biology, not to test a treatment. Results may not apply to people with blood pressure problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-40 years 2. BMI between 18.5 and 29.9 kg/m2 (both included) 3. Informed consent Exclusion Criteria: 1. Allergy or intolerance to ingredients included in the mixed meal 2. History of Orthostatic Hypotension (OH) or Postural Orthostatic Tachycardia Syndrome (POTS) or other autonomic dysfunction at the discretion of the investigators 3. Anaemia (haemoglobin below normal range \<7.3 mmol/L for women and \<8.3 mmol/L for men) 4. Kidney disease (estimated glomerular filtration rate (eGFR) \<90 ml/min/1.73 m2) at screening 5. Known liver disease and/or elevated plasma alanine aminotransferase (ALT) \> three times the upper limit of normal at screening 6. Treatment with antihypertensives 7. Treatment with GLP-1RA (Glucagon-like Peptide-1 Receptor Agonist) 8. Treatment with SNRI (Serotonin and Noradrenalin Reuptake Inhibitor) or treatment within two weeks before the first experimental day 9. Any ongoing medication that the investigator evaluates would interfere with trial participation 10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses 11. Any concomitant disease or treatment that, at the discretion of the investigators, might jeopardize the participant's safety during the trial 12. Alcohol/drug abuse as per discretion of the investigators 13. Pregnancy or breastfeeding 14. Participation in any other clinical trial during the study period 15. Mental incapacity or language barriers that preclude adequate understanding or cooperation or unwillingness to comply with trial requirements or pr discretion of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bloodpressure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Clinical Metabolic Research

    NOT_YET_RECRUITING

    Copenhagen, Hellerup, 2900, Denmark

  • Center for Clinical Metabolic Research

    RECRUITING

    Copenhagen, Hellerup, 2900, Denmark